levels of healthcare worker satisfaction as reported elsewhere (IAS, 2011). This study has resulted in measurable improvements to the health system including: the development of robust internal and external laboratory quality assurance (QA) systems and an integrated training for health workers on congenital syphilis prevention, treatment and quality assured use of PoC technologies. Use of integrated registers in MCH for data collection allowed for seamless initiation of the service into ANC. Supply chain systems were developed and enhanced especially in Uganda where syphilis testing was previously not routine. 13 131 women in Uganda and 12 761 women in Zambia received syphilis testing during the 5 month study period with a significant number of tests successfully carried out by nurse/midwives. Integrating syphilis and HIV supply chains led to reduced days of stock out of HIV test kits due to better ordering practices in some sites and did not negatively impact or integration significantly improved HIV service uptake.

Conclusions In addition to being acceptable, feasible and affordable, the systematic introduction of a PoC diagnostic for syphilis can lead to wider health system improvements and enhanced HIV service uptake in ANC. Wider use of PoC technologies is encouraged.

Abstract S4.2 Table1 Uptake of HIV services in sites with concurrent rapid syphilis testing

	Baseline	Rapid syphilis test study period	Result
	Zambia		
HIV testing	7,479 (95.5%)	11 151 (97.7%)	(χ^2=74.75; p<0.0001)
ARV prophylaxis	1,303 (98.3%)	2,036(100.1%)	(χ^2=35.56; p<0.0001)
Referral to care and treatment	977 (75%)	1,721(84.6%)	(χ^2=60.63; p<0.0001)
	Uganda		
HIV testing	6,479 (95.6%)	11 192 (96.4%)	(χ^2=7.01; p=0.008)
ARV prophylaxis	570 (78.5%)	964 (83.6%)	(χ^2=7.72; p=0.006)
Referral to care and treatment	85 (16.9%)	118 (16.1%)	(χ^2=0.168; p=0.68)

S4.3 IMPLEMENTATION OF RAPID TESTS FOR PRENATAL SYPHILIS SCREENING: OVERCOMING HEALTH SYSTEM CONSTRAINTS

doi:10.1136/sextrans-2011-050102.16

[1]P J Garcia, [2]R Peeling, [2]D Mabey, [3]K K Holmes, The CISNE team (Spanish word for SWAN). *[1]Universidad Peruana Cayetano Heredia, Lima, Peru; [2]London School of Hygiene and Tropical Medicine, London, UK; [3]University of Washington, Seattle, USA*

Background Congenital syphilis and syphilis in pregnancy in Peru persist as important public health issues, and improvement of screening/treatment for pregnant women remains challenging. rapid syphilis testing (RST) allows simple and immediate diagnosis and treatment at a single clinic visit and could increase screening and treatment coverage and thereby reduce the incidence of stillbirth and congenital syphilis and generate in the long term a sustainable cost effective intervention.

Methods We tested the feasibility, performance, impact and cost-effectiveness of implementing RST in an underserved urban area at a biggest maternity hospital in Peru and a network of 16 peripheral health centres offering prenatal care in a periurban poor area in Callao-Ventanilla, Peru. RST (integrated with HIV rapid test: the "two for one") were offered at the first prenatal visit (ANC), at delivery and within miscarriage/abortion services.

Results Data from the baseline pre-implementation evaluation revealed limited coverage of screening and treatment services for maternal syphilis and a complex and inefficient system for ANC. RST was started in January 2010. Overall success of implementation was measured by rates of maternal syphilis screening and treatment coverage, partner treatment, and acceptability of RST among providers and patients. Complementary evaluations comparing cost-effectiveness of RST against the Rapid Plasma Reagin, and a performance analysis of RST against the "multiple gold test" [Rapid Plasma Reagin + *Treponema pallidum* particle agglutination assay or fluorescent treponemal antibody absorption] were also simultaneously performed. Attention was paid to the successful development of a system of internal and external quality control for testing and test supplies and the process of dissemination and transfer activities to the Ministry of Health of Peru, through the involvement of both the National Program of STIs and HIV and the Reproductive Health Program. National guidelines have been modified, and recommend the use of both tests, RST and rapid HIV testing in the screening of pregnant women.

Conclusions RST implementation was feasible, successful, acceptable and cost effective. Its introduction catalysed improvements in the quality of care, and by the end of the project it has been introduced in the country as a national policy.

S4.4 PROGRESS IN DEVELOPMENT OF DUAL RAPID SYPHILIS TEST TECHNOLOGY

doi:10.1136/sextrans-2011-050102.17

D L Cox. *CDC, Atlanta, USA*

Background Traditionally, most diagnoses of syphilis relies on serology and required testing for patient antibodies against cardiolipin (non-treponemal tests) as well as against treponemal antigens (treponemal tests). These serological tests must be performed in clinical laboratories, require considerable scientific resources and trained technicians to perform them, and test results often are not reported for several days. As a result, control in resource-poor countries has been problematic. Rapid tests provide a platform whereby patient antibodies can be quickly analysed (5–30 min) by their binding to immobilised antigens on a nitrocellulose membrane. Another advantage is that patient sera, blood, or plasma can be tested, thus requiring fewer resources and technician time to perform. One of the first rapid tests developed was the Abbot Determine (treponemal test results only) which has served as a useful rapid screening tool in some settings. Other treponemal only rapid tests include the Standard Diagnostics BioLine and the Fujirebio Espline. These rapid tests have a sensivitivity ranging from 92% to 100% and specificity ranging from 93.4 to 98.9% when compared to the TP-PA. The Eurostrip (Euromedi Equipment LTD, W. Harrow, UK), another treponemal only rapid test, was recently evaluated at CDC for a potential field study in Kenya. With 94 archived serum samples, the Eurostrip had a sensitivity of 98.6% and a specificity of 100% when compared to the TP-PA.

Methods and results A recent breakthrough in technology allows for modified cardiolipin to be attached to membranes, and the first generation of dual rapid tests were developed in collaboration with CDC: the ChemBio DPP Screen and Confirm (ChemBio Diagnostic Systems, Medford, New York, USA) and the Span Spirolipin (Span Diagnostics Inc., Surat, India). In a study with 1601 archived serum samples, the non-treponemal component of the ChemBio DPP had a sensitivity of 97.3% and a specificity of 98.6% when compared to the RPR; the treponemal component had a sensitivity of 97% and a specificity of 95.5% when compared to the TP-PA. In a similar study with 376 archived serum samples, the non-treponemal component of the Span Spirolipin had a sensitivity of 96.5% and a specificity of 97.7% when compared to the RPR and the treponemal component had a sensitivity of 97.3% and a specificity of 99.1% when compared to the TP-PA. These evaluations demonstrate that these dual rapid tests are as sensitive and as specific as traditional RPR and TP-PA tests.

Conclusions The emergence of dual rapid tests offers resource-poor countries the opportunity for improved point-of-care diagnostic